Search results
Results from the WOW.Com Content Network
A drug recall removes a prescription or over-the-counter drug from the market. Drug recalls in the United States are made by the FDA or the creators of the drug when certain criteria are met. When a drug recall is made, the drug is removed from the market and potential legal action can be taken depending on the severity of the drug recall. [1]
Personalized Drug Lists: Users can create and manage lists of frequently used medications. Notifications : Alerts for new drug approvals, recalls, and updates to existing drug information. Search Functionality : Easy-to-use search tools to quickly find drug information.
Recalled Prograf is 0.5 mg strength, in 100-count bottles from lot No. 0E3353D. The recalled Astagraf comes in 30-count bottles of 0.5 mg strength from lot No. 0R3092A. Both have the expiration ...
Miglustat is indicated to treat adults with mild to moderate type I Gaucher disease for whom enzyme replacement therapy is unsuitable. [14]In the European Union, miglustat (Opfolda), in combination with cipaglucosidase alfa, is a long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α‑glucosidase [GAA] deficiency).
More than 233,000 bottles of an antidepressant have been recalled by public health officials due to a chemical containing the risk of cancer.. The U.S. Food and Drug Administration classified ...
Diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group. This drug continues to be available in most of the world including the US, but under strict controls. Terfenadine (Seldane, Triludan) 1997–1998 France, South Africa, Oman, others, US Prolonged QT interval; ventricular tachycardia [2] [3]
According to the announcement, the capsules were recalled when a batch of the medicine was accidentally released and shipped after being "rejected" due to potential foreign material contamination ...
The results were measured as mean monthly migraine days in months 4, 5, and 6. At baseline the patients experienced between 4 and 14 migraine days per month with an average of 8.3. The medication significantly reduced the number of migraine days per month by 3.2 in the 70-mg group and 3.7 in the 140-mg group, versus 1.8 in the placebo (0-mg) group.